GoAI
Get started
Theravance Biopharma Inc logo

Theravance Biopharma Inc

TBPH

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$17.005

−$0.005 · -0.03%

Aug 24, 10:27 AM ETData delayed

TBPH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

87

Deep Value

Momentum

59

Neutral

Sentiment

58

Mixed

Risk resilience

73

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Rick E. Winningham
Listed since
May 16, 2014
Employees
90

Market position

Day range

Current $17.005

52-week range

Current $17.005

Open
$16.99
Previous close
$17.01
Volume
24.21K
0.04× average
Average volume
556.58K
Average daily volume
Market cap
881.34M USD
Beta
0.17
Market reference 1
50-day average
$16.9048
+0.59% above average
200-day average
$17.2549
-1.45% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
849.12M USD
P/E (TTM)
15.99×
P/B (TTM)
3.03×
P/S (TTM)
8.45×
EV / EBITDA
6.19×
Earnings yield
11.25%
Free cash flow yield
25.33%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
89.40%
Operating margin
4.46%
Net margin
51.58%
Return on equity
35.69%
Return on assets
21.81%
Return on invested capital
-2.37%

Financial health

Debt / equity
0.13×
Current ratio
10.93×
Altman Z-score
2
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1915%1049%183%-683%Gross margin, FY2021: -250.12%Gross margin, FY2022: -23.46%Gross margin, FY2023: 29.26%Gross margin, FY2024: 41.53%Gross margin, FY2025: 94.87%Operating margin, FY2021: -466.06%Operating margin, FY2022: -179.09%Operating margin, FY2023: -97.58%Operating margin, FY2024: -72.92%Operating margin, FY2025: -12.33%Net margin, FY2021: -360.55%Net margin, FY2022: 1698.54%Net margin, FY2023: -96.11%Net margin, FY2024: -87.63%Net margin, FY2025: 98.54%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -250.12%. Gross margin FY2022 -23.46%. Gross margin FY2023 29.26%. Gross margin FY2024 41.53%. Gross margin FY2025 94.87%. Operating margin FY2021 -466.06%. Operating margin FY2022 -179.09%. Operating margin FY2023 -97.58%. Operating margin FY2024 -72.92%. Operating margin FY2025 -12.33%. Net margin FY2021 -360.55%. Net margin FY2022 1698.54%. Net margin FY2023 -96.11%. Net margin FY2024 -87.63%. Net margin FY2025 98.54%.

Income trends

Revenue

107.46M USD+66.92%

Operating income

−13.25M USD+71.79%

Net income

105.9M USD+162.31M USD
Income trends across reported periods985.12M USD533.16M USD81.19M USD−370.78M USDRevenue, FY2021: 55.31M USDRevenue, FY2022: 51.35M USDRevenue, FY2023: 57.42M USDRevenue, FY2024: 64.38M USDRevenue, FY2025: 107.46M USDOperating income, FY2021: −257.78M USDOperating income, FY2022: −91.96M USDOperating income, FY2023: −56.04M USDOperating income, FY2024: −46.95M USDOperating income, FY2025: −13.25M USDNet income, FY2021: −199.43M USDNet income, FY2022: 872.13M USDNet income, FY2023: −55.19M USDNet income, FY2024: −56.42M USDNet income, FY2025: 105.9M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 55.31M USD. Revenue FY2022 51.35M USD. Revenue FY2023 57.42M USD. Revenue FY2024 64.38M USD. Revenue FY2025 107.46M USD. Operating income FY2021 −257.78M USD. Operating income FY2022 −91.96M USD. Operating income FY2023 −56.04M USD. Operating income FY2024 −46.95M USD. Operating income FY2025 −13.25M USD. Net income FY2021 −199.43M USD. Net income FY2022 872.13M USD. Net income FY2023 −55.19M USD. Net income FY2024 −56.42M USD. Net income FY2025 105.9M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue107.46M USD64.38M USD57.42M USD51.35M USD55.31M USD
Cost of goods sold5.52M USD37.64M USD40.62M USD63.39M USD193.66M USD
Gross profit101.95M USD26.74M USD16.8M USD−12.05M USD−138.35M USD
Research and development37.41M USD38.05M USD46.34M USD70.07M USD201.55M USD
Selling, general, and administrative73.65M USD69.17M USD70.45M USD67.07M USD99.3M USD
Operating expenses115.2M USD73.69M USD72.84M USD79.91M USD119.44M USD
Interest income—4.88M USD9.12M USD8.55M USD1.11M USD
Interest expense2.46M USD2.55M USD2.35M USD6.37M USD8.55M USD
Depreciation and amortization5.52M USD3.62M USD2M USD3.04M USD4.81M USD
Operating income−13.25M USD−46.95M USD−56.04M USD−91.96M USD−257.78M USD
Net income105.9M USD−56.42M USD−55.19M USD872.13M USD−199.43M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
+47.52%
11 comparable reports
Latest EPS result
-0.11
Estimate 0.07 · Miss by 251.72%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.190.650.12-0.42Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual -0.31, estimate -0.171, surprise -81.19%, Miss. Q2 2025, reported May 8, 2025: actual -0.27, estimate -0.206, surprise -31.21%, Miss. Q3 2025, reported Aug 12, 2025: actual 1.08, estimate -0.085, surprise +1370.59%, Beat. Q4 2025, reported Nov 10, 2025: actual 0.04, estimate -0.12, surprise +133.33%, Beat. Q1 2026, reported Mar 19, 2026: actual 0.06, estimate 0.44, surprise -86.36%, Miss. Q2 2026, reported May 7, 2026: actual -0.096, estimate 0.028, surprise -443.57%, Miss. Q3 2026, reported Aug 10, 2026: actual -0.11, estimate 0.073, surprise -251.72%, Miss. Q4 2026, reported Nov 10, 2026: actual —, estimate 0.24, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates59.88M44.28M28.68M13.08MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 18.75M USD, estimate 17.03M USD, surprise +10.13%, Beat. Q2 2025, reported May 8, 2025: actual 15.39M USD, estimate 15.58M USD, surprise -1.20%, Miss. Q3 2025, reported Aug 12, 2025: actual 26.2M USD, estimate 25.93M USD, surprise +1.00%, Beat. Q4 2025, reported Nov 10, 2025: actual 19.99M USD, estimate 19.96M USD, surprise +0.15%, Beat. Q1 2026, reported Mar 19, 2026: actual 45.89M USD, estimate 56.59M USD, surprise -18.90%, Miss. Q2 2026, reported May 7, 2026: actual 17.7M USD, estimate 17.78M USD, surprise -0.47%, Miss. Q3 2026, reported Aug 10, 2026: actual 20.73M USD, estimate 22.49M USD, surprise -7.84%, Miss. Q4 2026, reported Nov 10, 2026: actual —, estimate 21.95M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$15.50

8.85% downside
Past 12 months12-month forecastHigh $17.00Average $15.50Low $14.00

Rating distribution

17 ratings
Strong buy00%
Buy424%
Hold1059%
Sell318%
Strong sell00%

Recent analyst actions

7 institutions
Jones TradingdowngradeBuyHold
OppenheimerdowngradeOutperformPerform
Leerink PartnersdowngradeOutperformMarket Perform

TBPH news

defenseworld.net

Empowered Funds LLC Purchases Shares of 55,463 Theravance Biopharma, Inc. $TBPH

Empowered Funds LLC acquired a new position in Theravance Biopharma, Inc. (NASDAQ: TBPH) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The…

Read source
gurufocus.com

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share.Hal

Read source
businesswire.com

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. Halper Sadeh encourages Theravance…

Read source
zacks.com

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.

Read source
prnewswire.com

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Previously announced acquisition by Zymeworks expected to close in second half of 2026 YUPELRI ® Collaboration Revenue increased 11% year-over-year 1, from $18.7 million to $20.7 million, driven by continued Net Sales…

Read source
defenseworld.net

Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its holdings in Theravance Biopharma, Inc. (NASDAQ: TBPH) by 14.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange…

Read source

TBPH peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

ETFs holding TBPH

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
21.85M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.81-0.38%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
17.5M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.76-0.40%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
7.36M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$244-0.62%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
6.06M
Weight
0.06%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$210.74-1.32%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
5.31M
Weight
0.04%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$383.58-0.98%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
4.99M
Weight
0.89%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$71.965-1.15%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.82M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.78-0.39%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
3.01M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.45-1.11%

Continue in GoAI

Research TBPH

research.disclaimer